How Much Money Do Pharmaceutical Companies Make From Psycotropic Drugs

APA's annual coming together is one of the largest medical meetings in the United States and the largest psychiatric meeting in the globe. At that place is something for everyone at our wonderful coming together, but many have commented to me on the extraordinary presence of the pharmaceutical industry throughout the scientific programs and on the exhibit floor.

The U.S. pharmaceutical manufacture is ane of the most profitable industries in the history of the world, averaging a render of 17 percent on acquirement over the last quarter century. Drug costs have been the most speedily rising element in health care spending in recent years. Antidepressant medications rank tertiary in pharmaceutical sales worldwide, with $13.4 billion in sales concluding year lone. This represents 4.ii per centum of all pharmaceutical sales globally. Antipsychotic medications generated $6.v billion in acquirement.

When the profit motive and human expert are aligned, it is a" win-win" situation. Pharmaceutical companies have adult and brought to market medications that have transformed the lives of millions of psychiatric patients. The proven effectiveness of antidepressant, mood-stabilizing, and antipsychotic medications has helped sensitize the public to the reality of mental illness and taught them that handling works. In this way, Big Pharma has helped reduce stigma associated with psychiatric treatment and with psychiatrists. My comments that follow on the pharmaceutical industry and its relationship to psychiatry acquit this in listen.

The interests of Big Pharma and psychiatry, however, are oft not aligned. The do of psychiatry and the pharmaceutical industry have unlike goals and abide by different ethics. Big Pharma is a concern, governed by the motive of selling products and making money. The profession of psychiatry aims to provide the highest quality of psychiatric care to persons who suffer from psychiatric conditions. There is widespread business concern of the over-medicalization of mental disorders and the overuse of medications. Financial incentives and managed care take contributed to the notion of a "quick gear up" by taking a pill and reducing the emphasis on psychotherapy and psychosocial treatments. There is much evidence that there is less psychotherapy provided past psychiatrists than 10 years agone. This is truthful despite the potent evidence base of operations that many psychotherapies are effective used lonely or in combination with medications.

In my last column, I shared with you my experience, and APA's, in responding to the antipsychiatry remarks that Tom Cruise fabricated before this summertime as he publicized his new movie in a succession of media interviews. One of the charges against psychiatry that was discussed in the resultant media coverage is that many patients are being prescribed the wrong drugs or drugs they don't demand. These charges are truthful, but it is not psychiatry's fault—information technology is the fault of the cleaved health care organisation that the Us appears to exist willing to endure. Equally we address these Large Pharma issues, we must examine the fact that every bit a profession, we accept allowed the biopsychosocial model to get the bio-bio-bio model. In a time of economical constraint, a "pill and an appointment" has dominated treatment. We must piece of work hard to end this state of affairs and go involved in advocacy to reform our health intendance system from the bottom up.

Furthermore, standing medical education opportunities sponsored by pharmaceutical companies are often biased toward one product or some other, and they are more akin to marketing than CME. APA has strict guidelines for the industry-sponsored symposia presented at our almanac meetings; sanctions are practical when our rules are broken. Our guidelines have been held up as a standard for medical meetings in other specialties throughout the country. But there are many grand rounds, evening dinners, and lectures where such standards practice not prevail.

Directly marketing to consumers likewise leads to increased demand for medications and inflates expectations about the benefits of medications. Every bit a profession, we demand to be concerned almost advertising and the impact information technology has on the over-medicalization of our field. Of course, what is marketed to consumers are the highest-cost, on-patent products, and the toll of medications is something rarely considered by prescribing clinicians. When doctors don't prescribe cheaper simply every bit effective drugs, information technology consumes money that could have been used to provide other psychiatric or medical services.

There are examples of the "ugly" practices that undermine the brownie of our profession. Drug company representatives will be the first to say that it is the doctors who request the fancy dinners, cruises, tickets to athletic events, and so on. Simply can we actually be surprised that several states have passed laws to strength disclosure of these gifts? And then-called" preceptorships" are another example of the "ugly"; that is, drug companies who pay physicians to allow company reps to sit in on patient sessions allegedly to learn more about intendance for patients and so advise the doctor on appropriate prescribing.

Drug company representatives bearing gifts are frequent visitors to psychiatrists' offices and consulting rooms. Nosotros should have the wisdom and altitude to call these gifts what they are—kickbacks and bribes. (For more than thoughts on this topic, encounter Viewpoints on Original article: page 33.) If we are seen equally mere pill pushers and employees of the pharmaceutical industry, our brownie as a profession is compromised.

Here are several suggestions for remedies in our human relationship with the manufacture.

	Nosotros need to embrace a new professional person ethic. The doctor-patient relationship should not be a market-driven phenomenon.
	Preceptorships should be considered unethical.
	Enticements, gifts, parties, and and so on should be reined in because patients must believe that their doctor has their best interests in mind when a prescription is handed to them.
	We must re-evaluate single-sponsored medical education events and phase them out in favor of more general back up for CME forth with a conscientious policing of these events for bias.
	The amount and support received past individual clinicians and researchers from industry should be transparent and the data readily bachelor.
	When we attend lectures at annual meetings and other educational events, and read journals and textbooks, we should know very clearly about the manufacture support given to presenters and authors.

As psychiatrists, nosotros should all be grateful for the modern pharmacopia and the promise of even more than improvements in the time to come. At the aforementioned time, however, we must exist very mindful that nosotros cannot accept gratuities in the new medical marketplace. ▪

Source: https://psychnews.psychiatryonline.org/doi/full/10.1176/pn.40.16.00400003

Posted by: priscoarge1945.blogspot.com